Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

"Faces" of the day:

Klara Konstanze Pohl

Federica Piani

Cara Lavinia Shirin Rech

Kathrin Eller

Christine Moissl-Eichinger

Dajie Marschik

Eleonore Fröhlich

Konstantin Adrian Klötzer

Florian Moik

Marco Eigenfeld

Mahmoud Abdellatif

Benjamin Gottschalk

Christian Diener

Peter Marschik

Simon Sedej

Sascha Ahyai

Roland Malli

Wolfgang Graier

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Randall, L; Xiang, Y; Matsumoto, T; Giannarelli, D; Milla, DP; Lopez, KA; Acevedo, A; Vizkeleti, J; Salani, R; Nogueira-Rodrigues, A; Mejia, FC; Korach, J; Akilli, H; Lee, JY; Saevets, VV; Samouelian, V; Sehouli, J; Tharavichikul, E; Sukhin, V; Colombo, N; Chang, CL; Cueva, JF; Lalondrelle, S; Petru, E; Szamreta, E; Nguyen, AM; Yamada, K; Li, K; Pignata, S; Lorusso, D.
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.
Gynecol Oncol. 2025; 199:88-95 Doi: 10.1016/j.ygyno.2025.06.003
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Petru Edgar
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: OBJECTIVE: In ENGOT-cx11/GOG-3047/KEYNOTE-A18 (NCT04221945), pembrolizumab (vs placebo) + concurrent chemoradiotherapy (CCRT) followed by pembrolizumab (vs placebo) significantly improved progression-free survival and overall survival in participants with newly diagnosed, high-risk locally advanced cervical cancer (LACC). We report patient-reported outcomes (PROs) from the study. METHODS: Participants (≥18 years) with high-risk LACC (FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA) were randomized 1:1 to 5 cycles of pembrolizumab 200 mg or placebo Q3W plus CCRT, followed by 15 cycles of pembrolizumab 400 mg or placebo Q6W. CCRT was 5 cycles (optional 6th dose) of cisplatin 40 mg/m² Q1W plus external beam radiotherapy followed by brachytherapy. Secondary PRO endpoints included EORTC QLQ-C30 GHS/QoL and physical functioning subscales and EORTC QLQ-CX24 symptom experience scale; EQ-5D-5L visual analogue scale (VAS) was an exploratory endpoint. No alpha was assigned to the PRO analyses. RESULTS: 1008 (95.1 %) of 1060 randomized participants were included in the PRO full analysis set population. No meaningful between-group differences were observed for any of the prespecified PRO instruments. Between-group differences (95 % CIs) in least-squares mean score changes from baseline to week 36 (primary time point) were 0.57 (-2.34 to 3.49) for QLQ-C30 GHS/QoL, 0.64 (-1.54 to 2.82) for QLQ-C30 physical functioning, 0.54 (-1.02 to 2.09) for QLQ-CX24 symptom experience, and -0.55 (-2.97 to 1.86) for EQ-5D-5L VAS. Empirical mean score changes over time and the proportions of participants whose scores improved, remained stable, or deteriorated over time were similar between treatment arms. CONCLUSIONS: Pembrolizumab+CCRT did not negatively impact participants' health-related quality of life.
Find related publications in this database (Keywords): pembrolizumab; Chemotherapy; Locally advanced cervical cancer; Health-related quality of life; Patient-reported outcomes